Aspects and embodiments of the present invention generally include a device for patient self-administration of a prescribed medication. The device makes available for administration the precise quantity of medication constituting a dose at times designated by a health care provider (HCP). Preferably, the device also detects and transmits information to a remote management system accessible to the HCP, including detected attempts to tamper with the device. Advantageously, HCPs may render oversight and control over the device and its use to mitigate risks associated with patients self-administering medication without in-person supervision. This control may include establishing prerequisites the patient must meet prior to a dose being made available, or remote deactivation of the device. This oversight by the HCP may include patient-specific and aggregate data analysis for optimization of treatment or evaluation of the safety and efficacy of a treatment. Furthermore, this oversight may be conducted via a web-based interface.

A method is provided that includes intranasally dispensing nasal wash fluid into a nasal cavity of a subject such that the nasal wash fluid washes biological material into an oropharynx of the subject from (a) the nasal cavity, (b) a nasopharynx of the subject, or (c) the nasal cavity and the nasopharynx. The method further includes, thereafter, collecting a specimen sample that passed out of an anterior opening of an oral cavity of the subject and contains at least a portion of the biological material washed into the oropharynx by the nasal wash fluid. Thereafter, information is derived from extracellular vesicles present in the specimen sample. Other embodiments are also described.

A method is provided that includes intranasally dispensing nasal wash fluid into a nasal cavity of a subject such that the nasal wash fluid washes biological material into an oropharynx of the subject from (a) the nasal cavity, (b) a nasopharynx of the subject, or (c) the nasal cavity and the nasopharynx. The method further includes, thereafter, collecting a specimen sample that passed out of an anterior opening of an oral cavity of the subject and contains at least a portion of the biological material washed into the oropharynx by the nasal wash fluid. Thereafter, information is derived from extracellular vesicles present in the specimen sample. Other embodiments are also described.

Proposed devices operate on positive pressure with as little as 5-6 ml of air and can efficiently empty (emitted doses >80%) and deliver the aerosol to infant lungs (lung delivery efficiency of ˜60% of the loaded dose). Significant features include internal flow structure of the air-jet DPI, automatic gas sources, infant-specific interfaces, small diameter nasopharyngeal tubes, sealed nasal prongs, 3D rod array preceding patient interface, nasal CPAP rapid aerosol delivery system, nasal CPAP streamlined interface, multidose storage and delivery unit, and pressure sensing near the infant airways (at the nasal cannula interface).

Proposed devices operate on positive pressure with as little as 5-6 ml of air and can efficiently empty (emitted doses >80%) and deliver the aerosol to infant lungs (lung delivery efficiency of ˜60% of the loaded dose). Significant features include internal flow structure of the air-jet DPI, automatic gas sources, infant-specific interfaces, small diameter nasopharyngeal tubes, sealed nasal prongs, 3D rod array preceding patient interface, nasal CPAP rapid aerosol delivery system, nasal CPAP streamlined interface, multidose storage and delivery unit, and pressure sensing near the infant airways (at the nasal cannula interface).

A nozzle (10) for a container for the intranasal administration of a liquid formulation comprises a nozzle body (12) with an upper end (18) and a lower end (16), a channel (40) traversing the nozzle body (12) and ending with an orifice (17) in the upper end (18), and a nozzle cover (14) covering an area of the outer surface of the nozzle body (12) which is designed to be introduced into a user's nostril, wherein the nozzle body (12) is made out of a first material and the nozzle cover (14) is made out of a second material, said first material being a rigid plastic material, and said second material being an elastic plastic material, and wherein the nozzle cover (14) is not in contact with the orifice (17). A packaging for a liquid formulation for intranasal administration comprises a container and such nozzle (10). A product comprises such a packaging and a liquid formulation in said packaging.

A nozzle (10) for a container for the intranasal administration of a liquid formulation comprises a nozzle body (12) with an upper end (18) and a lower end (16), a channel (40) traversing the nozzle body (12) and ending with an orifice (17) in the upper end (18), and a nozzle cover (14) covering an area of the outer surface of the nozzle body (12) which is designed to be introduced into a user's nostril, wherein the nozzle body (12) is made out of a first material and the nozzle cover (14) is made out of a second material, said first material being a rigid plastic material, and said second material being an elastic plastic material, and wherein the nozzle cover (14) is not in contact with the orifice (17). A packaging for a liquid formulation for intranasal administration comprises a container and such nozzle (10). A product comprises such a packaging and a liquid formulation in said packaging.

Provided is a pharmaceutical agent for effective prophylaxis and/or treatment of a pathological condition with decreased lung compliance. The pharmaceutical agent for prophylaxis and/or treatment of a pathological condition with decreased lung compliance is characterized by having a polyamine. The polyamine includes at least one of spermine (Spm), spermidine (Spd), and putrescine (Put). The pharmaceutical agent improves lung compliance and ameliorates gas exchange dysfunction, and therefore, can ameliorate pathological conditions such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI), lung diseases caused by dysfunctional endogenous pulmonary alveolar surfactant, multiple organ dysfunction syndrome (MODS), and cardiogenic pulmonary edema.

A method for characterizing an olfactory stimulation, including visual stimulation steps each associated with a theme and first steps of recording physiological variables carried out continuously during a first visual stimulation step, so as to obtain first physiological recordings, each first physiological recording being associated with the theme associated with the first visual stimulation step, a second olfactory stimulation step, a second step of recording values of physiological variables carried out continuously during and after the second olfactory stimulation step to obtain a second physiological recording, a step of comparing the first physiological recordings with the second physiological recording to isolate a first physiological recording close to the second physiological recording, and a step of determining a theme associated with the first physiological recording which is isolated during the comparing step.

A syringe type ejection device capable of reducing an amount of residual liquid is provided. A syringe type ejection device includes: a barrel; a nozzle disposed to face the barrel; and a core inserted in the nozzle, the barrel having a large-diameter portion provided with a discharge space for discharging liquid, the nozzle being provided with a holding space for holding the core, the holding space being in communication with the discharge space, and the core being inserted in the discharge space.